Acrivon Therapeutics, Inc. Common Stock (NASDAQ: ACRV) is a Healthcare company (Biotechnology) with a market capitalization of $61M. The Maz Rating grades it against the other companies in its sector.
Acrivon Therapeutics, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $1.43, Acrivon Therapeutics, Inc. Common Stock trades at 0.9x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -80.9%, return on invested capital of -106.4% and a free cash flow yield of -102.6%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 5.54. Over the past 52 weeks the share price ranged from $1.27 to $3.56, with a beta of 1.98.
Acrivon Therapeutics, Inc. Common Stock does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 9 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.